HOME >> BIOLOGY >> NEWS
Treatment extends survival in mouse model of spinal muscular atrophy

Drug therapy can extend survival and improve movement in a mouse model of spinal muscular atrophy (SMA), new research shows. The study, carried out at the NIHs National Institute of Neurological Disorders and Stroke (NINDS), suggests that similar drugs might one day be useful for treating human SMA.

"This study shows that treatment can be effective when started after the disease appears," says Kenneth H. Fischbeck, M.D., of the NINDS, who helped lead the new study. The finding is important because most children with SMA are diagnosed after symptoms of the disease become obvious, he adds. The report appears in the February 22, 2007, advance online publication of The Journal of Clinical Investigation.*

SMA is the most common severe hereditary neurological disease of childhood, affecting one in every 8,000-10,000 children. Babies with the most common form of the disease, called SMA type I, develop symptoms before birth or in the first few months of life and have severe muscle weakness that makes it difficult for them to breathe, eat, and move. They usually die by age two. Other forms of SMA are not as severe, but still cause significant disability. While some symptoms of SMA can be alleviated, there is currently no treatment that can change the course of the disease.

SMA is caused by mutations in a gene called SMN1. Investigators studying the genetics of SMA have found that there is another gene, called SMN2, on the same chromosome. While the normal form of SMN1 produces a full-length functional protein, most of the protein produced by SMN2 is truncated and unable to function. The relatively small amount of normal SMN protein produced by the SMN2 gene can reduce the severity of the disease. Therefore, investigators are searching for drugs that can increase the amount of normal protein produced by this gene.

The new study, directed by Dr. Fischbeck's colleague Charlotte J. Sumner, M.D., at NINDS, tested a drug called trichostatin A
'"/>

Contact: Natalie Frazin
301-496-5924
NIH/National Institute of Neurological Disorders and Stroke
22-Feb-2007


Page: 1 2 3

Related biology news :

1. Treatment-induced growth factor causes cancer progression
2. Water Treatment and Reuse -- II
3. Treatments for urinary infections leave bacteria bald, happy and vulnerable
4. Treatment disconnect in kidney cancer: Rising mortality despite more small tumors, more surgery
5. Evolving Issues in the Prevention and Treatment of Influenza: A media forum
6. NHLBI media availability: Treatment shows long-term benefits for cystic fibrosis patients
7. Treatments have same target, different responses for lung cancer patients with genetic mutation
8. Back to the future: Mastodon extends the time limit on DNA sequencing
9. Wiley extends publishing partnership with the American Institute of Chemical Engineers
10. Nexavar significantly extends overall survival by 44 percent in liver cancer patients
11. Vitamin extends life in yeast, Dartmouth Medical School researchers find

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2020)... ... 2020 , ... With numerous products in its pipeline, Cytonus ... Cytonus’ existing products and to expand the companies’ intellectual property assets. Cytonus is ... located in Austria. , Phoenestra has developed IP assets in connection with ...
(Date:3/5/2020)... ... March 05, 2020 , ... Diagenode, a leading ... Tech (MGI), a subsidiary of global genomics leader BGI Group, today announced a ... States, Europe and Asia Pacific. , Under the terms of the non-exclusive ...
(Date:3/4/2020)... ... March 04, 2020 , ... The Massachusetts Medical Device Industry ... IGNITE program’s 2020 IGNITE Cohort. The MedTech IGNITE Program is a virtual accelerator ... next generation of medtech founders and entrepreneurs. IGNITE Cohort members get access to ...
Breaking Biology News(10 mins):
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will ... FL. The company will showcase both expanded and emerging offerings that align with the ... is designed to be comprehensive, timely, and engaging. From Interoperability and ...
(Date:2/28/2020)... ... February 26, 2020 , ... Designed primarily ... camera with a dedicated controller, thus simplifying setup, streamlining integration, and optimizing workflow. ... the first of Fastec Imaging’s new HS Series cameras to be released. The ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... chain transparency and reassuring consumers that what’s listed on an ingredient panel is ... Nutrition21 has introduced this solution with the adoption of CertainT, which is designed ...
(Date:2/19/2020)... (PRWEB) , ... February 18, 2020 , ... ... medical devices, today announced the launch of a new and unified global brand ... tackle the industry’s most complex engineering challenges, as well as an enthusiasm for ...
Breaking Biology Technology:
Cached News: